Quick Overview: Eran Ophir, PhD, Compugen Ltd.,Tel Aviv, Israel, discusses Eran Ophir, PhD, Compugen Ltd., Tel Aviv, Israel, discusses future research directions for Contents: Panel moderated by Dan Lovell: 0:00 - Fabrizio De Benedetti & Scott Canna : It is time for

Targeting Il18 With Com503 To - Detailed Overview & Context

Eran Ophir, PhD, Compugen Ltd.,Tel Aviv, Israel, discusses Eran Ophir, PhD, Compugen Ltd., Tel Aviv, Israel, discusses future research directions for Contents: Panel moderated by Dan Lovell: 0:00 - Fabrizio De Benedetti & Scott Canna : It is time for Long COVID in Autoimmune Patients: Could Low An international team of researchers from UMass Medical School, the University of Bonn and the Center for Advanced European ... Controlling the inflammation caused by IL-18. What the IL-18/IL-18BP tells us.

This focused session addresses optimal treatment strategies for patients with left main and complex bifurcation coronary lesions. Interleukin 1 Family has 11 members- IL-1 Alpha, IL-1 Beta, IL-1 Ra, Psoriasis is a chronic inflammatory skin disorder that affects about 2-3% of the population. It is triggered by the immune system, ...

Photo Gallery

Targeting IL18 with COM503 to treat cancer
Targeting IL18 in autoinflammatory diseases, Dr Ed Behrens
COM503: the next steps in harnessing cytokines to treat cancer
COM503: harnessing cytokine biology to treat cancer
It is Time for IL18 Driven Clinical Trials
Scott Canna: Targetting IL18
Long COVID and Autoimmunity: Is IL-18 the Missing Link?
Targeting a new therapy for Alzheimer's
Targeting cytokines in CRS-future trends-Dr.Randy Cron
IL-18: The Complex Cytokine in Immunity and Disease
Journal Club - Targeting interleukin 6 could help relieve immunotherapy side effects
Learn IL-18 in 3 minutes | Interleukin-18 (IL18)
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored